AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Covid-19 redefines rules of customer engagement: Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story: Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change: Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....